Document is current

Article History

Received: 17 January 2023

Accepted: 23 January 2023

First Online: 11 April 2023

Declarations

:

: This study was approved by the ethics committee of Kyoto University (approval number: C1534–1). This study will be conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent will be obtained from all participants.

: The study participants are informed that their anonymized data will be published in academic journals and provided written consent for publication. Dissemination of study findings will be undertaken through publications, seminars, and relevant written information to patient organizations.

: The Department of Advanced Medicine for Rheumatic Diseases is supported by Nagahama City, Shiga, Japan; Toyooka City, Hyogo, Japan; and five pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd., UCB Japan Co. Ltd., AYUMI Pharmaceutical Co., and Asahi Kasei Pharma Corp.). This study is also supported by grants from Daiichi Sankyo Co. Ltd. The above-mentioned pharmaceutical companies were not involved in the study design, manuscript writing, or manuscript submission and will not be involved in data collection and analysis.AO received research grants and/or speaker fees from Pfizer Inc., Bristol-Myers Squibb., Advantest, Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K. K., Ono Pharmaceutical Co., UCB Japan Co., Mitsubishi Tanabe Pharma Co., Eisai Co. Ltd., Abbvie Inc., Takeda Pharmaceutical Co. Ltd., and Daiichi Sankyo Co. Ltd. RU has received honorarium from Eisai Co. Ltd., Sawai Pharmaceutical Co. Ltd., and EPS Corporation, outside the work. HO received research grants and/or speaker fees from AbbVie, Asahi Kasei, Astellas Pharma Inc., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, and Daiichi Sankyo Co. Ltd. TF received speaker fees from Abbie, Asahi Kasei, Jansen, Tanabe Mitsubishi, and Eisai. K Murata received speaking fees and/or consulting fees from AbbVie GK, Eisai Co. Ltd., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Bristol-Myers Squibb, and Asahi Kasei Pharma Corp. K Murakami received speaking fees, and/or consulting fees from Eisai Co. Ltd., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma Corporation, UCB Japan Co. Ltd., Daiichi Sankyo Co. Ltd., and Astellas Pharma Inc. M Tanaka received research grants and speaker fees from AbbVie GK, Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly and Company, Pfizer Inc., UCB Japan Co. Ltd., Janssen Pharmaceutical K.K., Kyowa Kirin Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Taisho Pharma Co. Ltd., and Teijin Pharma, Ltd. AM received honoraria from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Eisai Co. Ltd., Pfizer Inc., Bristol-Myers Squibb., Mitsubishi Tanabe Pharma Co., Astellas Pharma Inc., and Gilead Sciences Japan and has received research grants from AbbVie G.K., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., and Eisai Co. Ltd. outside the work. MH received research grants and/or speaker fees from Abbvie, Asahi Kasei, Astellas, Ayumi, Bristol Meyers, Chugai, EA Pharma, Eisai, Daiichi Sankyo, Eli Lilly, Nihon Shinyaku, Novartis Pharma, and Tanabe Mitsubishi. M Torii, YH, YO, HT, SM, and HA have no competing interests to be reported.